Peptides Identified Through Phage Display for Prostate Cancer Imaging and Therapy

Prostate cancer is the second highest cause of cancer death among the world. It is important to identify the target molecules for prostate cancer early detection and targeted therapy. In this mini review, we discuss some of peptides identified through phage display for molecular imaging and targeted therapy of prostate cancer.

[1]  J. Frangioni.  In vivo near-infrared fluorescence imaging. , 2003, Current opinion in chemical biology.

[2]  A. M. Moro,et al.  Comparison of two peptide radiotracers for prostate carcinoma targeting , 2012, Clinics.

[3]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[4]  Ralph Weissleder,et al.  Near-infrared fluorescence: application to in vivo molecular imaging. , 2010, Current opinion in chemical biology.

[5]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[6]  Zheng-Rong Lu,et al.  Peptide targeted high-resolution molecular imaging of prostate cancer with MRI. , 2014, American journal of nuclear medicine and molecular imaging.

[7]  R G Newcombe,et al.  Preoperative assessment of prognostic factors in rectal cancer using high‐resolution magnetic resonance imaging , 2003, The British journal of surgery.

[8]  Brian R. McNaughton,et al.  Engineered M13 bacteriophage nanocarriers for intracellular delivery of exogenous proteins to human prostate cancer cells. , 2014, Bioconjugate chemistry.

[9]  J. Huston,et al.  In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. , 1995, Immunotechnology : an international journal of immunological engineering.

[10]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[12]  S. Deutscher.  Phage display in molecular imaging and diagnosis of cancer. , 2010, Chemical reviews.

[13]  W. Willats,et al.  Phage display: practicalities and prospects , 2002, Plant Molecular Biology.

[14]  A. Kratz,et al.  Prostate-specific antigen and the early diagnosis of prostate cancer. , 2002, American journal of clinical pathology.

[15]  Duanwen Shen,et al.  Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA) , 2013, PloS one.

[16]  S. Sidhu,et al.  Engineering M13 for phage display. , 2001, Biomolecular engineering.

[17]  Kimberly A Kelly,et al.  M13-templated magnetic nanoparticles for targeted in vivo imaging of prostate cancer. , 2012, Nature nanotechnology.

[18]  Chun Li,et al.  Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. , 2003, Cancer research.

[19]  Ralph Weissleder,et al.  In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. , 2006, Neoplasia.

[20]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[21]  T. V. van Berkel,et al.  Targeting of peptides to restenotic vascular smooth muscle cells using phage display in vitro and in vivo. , 2002, Biochimica et biophysica acta.

[22]  Carlos F. Barbas,et al.  Phage display: a Laboratory manual , 2014 .

[23]  Ralph Weissleder,et al.  Detection of early prostate cancer using a hepsin-targeted imaging agent. , 2008, Cancer research.

[24]  R. Sidman,et al.  Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors , 2015, Proceedings of the National Academy of Sciences.